Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyCommunity-Care ecallantide Coverage Prior Auth | O…
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Ecallantide (J1290) for Acute Hereditary Angioedema — Coverage Criteria

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical benefit coverage criteria, quantity limits, and authorization period for ecallantide (injection) used to treat acute attacks of hereditary angioedema for members of Community-Care.

    Policy Summary
    PayerCommunity-Care
    PolicyEcallantide (J1290) for Acute Hereditary Angioedema — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewDec 1, 2021
    Next Review DateDec 31, 2024
    Key ActionObtain prior authorization with documentation confirming hereditary angioedema, prescriber specialty or consultation with an allergist/immunologist, and evidence of icatibant trial or contraindication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 yearauthorization period when approved
    nonequantity limits for acute attacks
    J1290listed HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Ecallantide

    Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Acute hereditary angioedema coverage criteria

    • Prescribing and diagnosis

      • Prescribed by, or in consultation with, an allergist or immunologist
      • Confirmed diagnosis of hereditary angioedema
    • Prior therapy

      • Trial of icatibant (Firazyr) was ineffective, contraindicated, or not tolerated
    • Operational requirement

      • Medication is required to be on hand for acute treatment
    Authorization period: Coverage allowed for 1 year if approved

    None specified beyond the listed criteria.

    No additional exclusions or not-medically-necessary statements are specified in this policy beyond the coverage criteria and requirements already listed.

    Applicable Codes

    Applicable HCPCS CodesHCPCSCovered
    J1290Injection, ecallantide, 1 mg

    Provider Requirements and Authorization Rules

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for ecallantide (HCPCS J1290) for treatment of acute hereditary angioedema (HAE) attacks. Requests must document the indication, that the medication will be available for acute use, and meet the clinical criteria below.

    • Affected code: J1290 — Injection, ecallantide, 1 mg
    • Authorization period: up to 1 year if approved
    Step Therapy

    Step Therapy: Icatibant Trial Required

    A prior trial of icatibant (Firazyr) is required and must have been ineffective, contraindicated, or not tolerated before ecallantide will be authorized. If icatibant cannot be used for clinical reasons, documentation must explain the specific contraindication or intolerance.

    • Step requirement: documented trial of icatibant (Firazyr) OR documentation of contraindication/intolerance/ineffectiveness
    Documentation Required

    Required Documentation

    Documentation must confirm a diagnosis of hereditary angioedema and show that the prescriber is an allergist or immunologist, or that the treating prescriber consulted with an allergist/immunologist. Include clinical history of HAE attacks, prior therapies tried (including icatibant), and rationale for ecallantide.

    • Required documentation: confirmed HAE diagnosis
    • Prescriber requirement: prescribing clinician must be an allergist/immunologist or include documented consultation with one
    • Clinical details: attack history and prior treatment response
    Denial Risk

    Triggers for Denial

    Authorization may be denied if required documentation is missing or incomplete. Common triggers for denial include lack of confirmed HAE diagnosis, absence of documentation of icatibant trial or valid contraindication/intolerance, and prescribing by a clinician who is not a specialist without documented consultation.

    • Denial triggers: no confirmed HAE diagnosis
    • Denial triggers: no documentation of icatibant trial or documented contraindication/intolerance
    • Denial triggers: prescriber is not an allergist/immunologist and no consultation is documented

    Background

    Hereditary angioedema is characterized by recurrent acute attacks of swelling that may require on-demand treatment. Ecallantide is an injectable therapy indicated for treatment of acute attacks and is covered when specified criteria are met, including that it be prescribed by or in consultation with an allergist or immunologist, the member has a confirmed diagnosis of hereditary angioedema, a trial of icatibant (Firazyr) was ineffective, contraindicated, or not tolerated, and the medication will be kept on-hand for acute treatment.

    Definitions

    inv-10: acute attacks of hereditary angioedema — definition / key term
    TermAcute attacks of hereditary angioedema
    DefinitionRecurrent, episodic swelling events due to hereditary angioedema that require on‑demand treatment
    Typical treatment contextOn‑demand injectable therapies (ecallantide) when first‑line options are ineffective or unsuitable
    Authorization noteCoverage allowed when criteria met; if approved, authorization period is 1 year
    Quantity limitNone specified for acute attacks
    Policy Summary
    PayerCommunity-Care
    PolicyEcallantide (J1290) for Acute Hereditary Angioedema — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewDec 1, 2021
    Next Review DateDec 31, 2024
    Key ActionObtain prior authorization with documentation confirming hereditary angioedema, prescriber specialty or consultation with an allergist/immunologist, and evidence of icatibant trial or contraindication.
    SourceLink
    On This Page
    Coverage Criteria for EcallantideApplicable CodesProvider Requirements and Authorization RulesBackgroundDefinitions